Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 153 clinical trials
Featured trial
A 10-12 week study to evaluate an oral medication for itching related to eczema (atopic dermatitis).

A 10-12 week study to evaluate an oral medication for itching related to eczema (atopic dermatitis).

  • 468 views
  • 08 Nov, 2020
  • 1 location
Featured trial
Atopic Dermatitis or Eczema

This study is to see how safe and effective the topical spray on trial medication is when used on subjects with Pruritus or Itch with Atopic Dermatitis. 

topical agents
  • 2 views
  • 29 Jul, 2021
  • 1 location
Featured trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profile of ANB020 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis

This is a 24-week randomized, double blind, placebo controlled, parallel group, dose ranging, Phase 2b study designed to assess the efficacy of different doses and dose regimens of Etokimab compared to placebo in adult subjects with moderate to severe atopic dermatitis (AD). This study will also assess the safety, tolerability, …

  • 53 views
  • 23 Nov, 2020
  • 1 location
Featured trial
A Phase 2, Randomized, Dose-Ranging, Vehicle-Controlled and Triamcinolone 0.1% Cream–Controlled Study to Evaluate the Safety and Efficacy of INCB018424 Phosphate Cream Applied Topically to Adults With Atopic Dermatitis

A Phase 2, Randomized, Dose-Ranging, Vehicle-Controlled and Triamcinolone 0.1% Cream–Controlled Study to Evaluate the Safety and Efficacy of INCB018424 Phosphate Cream Applied Topically to Adults With Atopic Dermatitis

dermatitis
atopic dermatitis
atopic dermatitis/eczema
  • 1383 views
  • 08 Dec, 2020
  • 53 locations
Featured trial
An Open-Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis

An Open-Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis

dermatitis
eczema
atopic dermatitis
atopic dermatitis/eczema
  • 1408 views
  • 08 Dec, 2020
  • 4 locations
Featured trial
We are currently recruiting participants for the BLUEPRINT study. This study investigates the effectiveness, safety, and tolerability of the drug BLU-5937 for chronic itch in people with eczema.

The BLUEPRINT study consists of taking two tablets orally, twice a day, for a period of 4 weeks. This treatment is experimental. You will have 50% chance to receive BLU-5937 and 50% chance to receive the placebo. There will be a total of 5 visits at the clinic and 2 …

eczema
atopic dermatitis/eczema
dermatitis
atopic dermatitis
adult atopic dermatitis
  • 44 views
  • 10 Dec, 2020
  • 25 locations
Featured trial
INCB 18424-304: Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE-AD2) for 304

A Phase 3, randomized (2:2:1), double-blind, 8-week vehicle control efficacy and safety study of ruxolitinib followed by a randomized, double-blind, 44-week long term safety (LTS) extension period.  In the LTS period,  participants initially randomized to vehicle will receive either ruxolitinib 0.75% or 1.5% cream.  All participants will have follow-up assessments …

dermatitis
eczema
atopic dermatitis
atopic dermatitis/eczema
  • 379 views
  • 25 Aug, 2021
  • 11 locations
Featured trial
Atopic Dermatitis In Young Adults

Atopic Dermatitis is a chronic medical condition that has increased over the past two to three decades. It affects between 15-30% of children and 2-10% of adults. Local physicians are currently evaluating a trial medication for Atopic Dermatitis to see if it may help symptoms. Find out more!  

  • 48 views
  • 23 Nov, 2020
  • 1 location
Featured trial
INCB 18424-303: Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE-AD1)

A Phase 3, randomized (2:2:1), double-blind, 8-week vehicle control efficacy and safety study of ruxolitinib followed by a randomized, double-blind, 44-week long term safety (LTS) extension period.  In the LTS period,  participants initially randomized to vehicle will receive either ruxolitinib 0.75% or 1.5% cream.  All participants will have follow-up assessments …

eczema
atopic dermatitis
atopic dermatitis/eczema
  • 270 views
  • 25 Aug, 2021
  • 19 locations
Featured trial
A 3-week study to evaluate a generic non-steroidal topical cream for the treatment of eczema.

A 3-week study to evaluate a generic non-steroidal topical cream for the treatment of eczema.

  • 190 views
  • 08 Nov, 2020
  • 1 location